Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Earnings Results, Beats Estimates By $0.37 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $9.10 by $0.37, FiscalAI reports. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.45 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.22 earnings per share.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Regeneron reported strong Q1 2026 results with total revenues up 19%, non-GAAP EPS up 15%, $848M of free cash flow, $15.8B net cash, and a new $3B share repurchase authorization.
• Dupixent remains the company’s growth engine, with Q1 net sales up 31% (cc) to $4.9B and annualized global sales near $20B as approvals expand to younger patients and new indications.
• EYLEA HD adoption accelerated (U.S. net sales +52% to $468M) after label enhancements and increased physician uptake, and Regeneron expects FDA action this quarter on prefilled-syringe manufacturing applications.
• EYLEA (base) U.S. net sales declined 36% to $473M amid conversion to EYLEA HD, inventory absorption (expected to subtract ~ $20M from Q2 sales) and impending biosimilar competition; additionally, a temporary manufacturing interruption in Limerick reduced GAAP gross margin and led to updated GAAP margin guidance (~77%–78%).
• Pipeline momentum includes FDA approval of gene therapy Otarmeni (to be provided free), positive phase III cemdisiran data in generalized myasthenia gravis with an anticipated Q4 decision, a PDUFA in August for garetosmab (FOP), and promising olatorepatide data with global phase III plans.

Regeneron Pharmaceuticals Trading Down 6.5%

Shares of NASDAQ:REGN traded down $47.78 during trading on Wednesday, reaching $684.00. The stock had a trading volume of 1,243,029 shares, compared to its average volume of 738,327. The firm’s fifty day moving average is $760.43 and its 200 day moving average is $735.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market cap of $72.31 billion, a price-to-earnings ratio of 16.50, a P/E/G ratio of 1.71 and a beta of 0.40.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both EPS and revenue: Regeneron reported non‑GAAP EPS of $9.47 and revenue of ~$3.6B, topping estimates and showing 19% revenue growth — a strong near‑term financial print. Regeneron beats quarterly results estimates on strong Dupixent demand (Reuters)
• Positive Sentiment: Dupixent and EYLEA HD momentum: Dupixent demand remains a key growth driver (Sanofi‑reported Dupixent sales +33%); EYLEA HD U.S. adoption rose sharply (EYLEA HD U.S. net sales +52%), supporting medium‑term growth prospects. Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Zacks)
• Positive Sentiment: $3B buyback announced: Management authorized up to $3 billion in share repurchases, which supports EPS and signals management confidence. Regeneron shares slide despite Q1 beat (ProactiveInvestors)
• Neutral Sentiment: Pipeline milestones could be value drivers but are not immediate: Progress in the C5 complement program (PNH enrollment complete) and positive Phase III data for cemdisiran in myasthenia gravis set up potential multi‑indication launches as early as Q4 2026 — longer‑term upside if approvals materialize. Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation (Yahoo)
• Neutral Sentiment: Full earnings call details and management commentary available for color on margins, IPR&D impacts and product cadence — useful for modeling but not a single catalyst. Regeneron Q1 2026 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: EYLEA U.S. sales disappointed vs. Street expectations: Despite HD uptake, total EYLEA U.S. net sales declined ~10% and reported U.S. high‑dose sales missed expectations, fueling the intraday selloff. Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug (Yahoo)
• Negative Sentiment: Rising competition and upcoming biosimilars/new entrants: Analysts flag intensified competition in the retina market and several competitors with data or launches coming later this year, which could pressure EYLEA revenue and valuation going forward. Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. (Yahoo)

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Kemnay Advisory Services Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Birchwood Financial Partners Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $32,000. Transamerica Financial Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 380.0% during the fourth quarter. Transamerica Financial Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 38 shares during the last quarter. Graney & King LLC raised its holdings in Regeneron Pharmaceuticals by 6,800.0% during the fourth quarter. Graney & King LLC now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 68 shares during the last quarter. Finally, Truvestments Capital LLC raised its holdings in shares of Regeneron Pharmaceuticals by 101.9% in the fourth quarter. Truvestments Capital LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Evercore lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Piper Sandler began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $825.35.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.